

Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Cardiovascular and Renal Drugs Advisory Committee
March 18, 2009

Marriott Conference Centers,
UMUC Inn and Conference Center by Marriott,
3501 University Blvd., East, Adelphi, MD

DRAFT Agenda

8:00 a.m.	Call to Order Introduction of Committee	Robert A. Harrington Chair, CRDAC
	Conflict of Interest Statement	Elaine Ferguson, M.S., R.Ph. Designated Federal Official, CRDAC

The committee will discuss new drug application (NDA) 22-425, dronedarone 400 milligrams oral tablets, Sanofi Aventis, for the proposed indication in patients with a history of, or current atrial fibrillation or atrial flutter, for the reduction of the risk of cardiovascular hospitalization or death.

8:05 a.m.	FDA Opening Remarks	Norman Stockbridge, M.D. Director, Cardiovascular and Renal Drug Products, CDER
8:15 a.m.	<u>Sponsor Presentations</u> Introduction	Richard Gural, Ph.D. Sanofi-Aventis
	Unmet Medical need in Patients with Atrial Fibrillation/Flutter: Rate and Rhythm Control Studies	Gerald Naccarelli, M.D. Hershey Medical Center
	Effect of Dronedarone on Major Cardiovascular Events: The ANDROMEDA and ATHENA Trials	Milton Packer, M.D. UT Southwestern Medical Center at Dallas
	Safety of Dronedarone in Atrial Fibrillation/Flutter Trials	Paul Chew, M.D. Sanofi-Aventis
	Benefit-Risk of Dronedarone Implications for Patients and Physicians	John Camm, B.Sc., M.D., F.R.C.P St. George's, University of London
	Questions to the Sponsor	
10:00 a.m.	<u>Break</u>	
10:15 a.m.	<u>FDA Presentations</u>	Abraham Karkowsky, M.D. Medical Officer, Cardiovascular and Renal Drug Products, CDER
11:00 a.m.	Questions to the FDA	
12:00	<u>Lunch</u>	

Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Cardiovascular and Renal Drugs Advisory Committee
March 18, 2009

Marriott Conference Centers,
UMUC Inn and Conference Center by Marriott,
3501 University Blvd., East, Adelphi, MD

DRAFT Agenda

- | | |
|-----------|---|
| 1:00 p.m. | Open Public Hearing |
| 2:00 p.m. | Questions to Sponsor and FDA
Discussion of questions to
committee |
| 3:30 p.m. | <u>Break</u> |
| 3:15 p.m. | Discussion of questions to
committee (continued) |
| 5:00 p.m. | Adjourn |